top of page

A Study of the Safety and Tolerability of AB-2004 in a Pediatric Autism Spectrum Disorder Population

We are working with Axial and three other sites to assess the safety, tolerability and efficacy of a pharmaceutical therapy called AB-2004.

Phase 1b/2a of the study explored whether AB-2004’s ability to reduce the availability of certain gut bacteria, such as p-cresol, can improve gastrointestinal symptoms and some related behavioural challenges in autistic individuals.

Phase 2b of the study is now underway, investigating whether treatment with AB-2004 can improve irritability in autistic children. Eligible participants will be randomly assigned to receive AB-2004 or a placebo.

You can read more on the study's website

Recruitment

To be eligible, participants must be:

  • Male, aged 12 - <18 years old.

  • Have an autism diagnosis

  • Experience irritability

  • Have no medical conditions as described in the exclusion criteria

This study is currently OPEN. Register your interest below. 

Initial findings are promising and can be read about here.

 

Initial findings are promising and can be read about here.

Results

bottom of page